US4244956A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating inflammation
Assignee: ADA Forsyth Institute Inc
•
Filing: 1979-11-26
•
Granted: 1981-01-13
•
Expires: 1999-11-26
Abstract
Abstract A method of treating inflammation and inhibiting prostaglandin synthesis employing substituted 2-(arylmethoxy)phenol compounds.
Inventors
- 👤 Floyd E. Dewhirst
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 05:57
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/075; A61K31/085; A61K31/09; A61K31/41; A61K31/415; A61K31/44; C; C07; C07C; C07C43/00; C07C43/02; C07C43/20; C07C43/23
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
83 words
A method of treating inflammation in mammals, which method comprises administering to the mammal a therapeutical effective amount of a compound of the formula: ##STR3## where X is selected from the group consisting of: (a) naphthyl, pyridyl, quinolyl and 2-benzimidazolyl; and (b) a substituted phenyl having the structural formula ##STR4## where R, R' and R" are hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or combinations thereof and the nontoxic pharmaceutically acceptable salts thereof.
Claim 2
Independent Claim
83 words
A method of treating inflammation in mammals, which method comprises administering to the mammal a therapeutical effective amount of a compound of the formula: ##STR3## where X is selected from the group consisting of: (a) naphthyl, pyridyl, quinolyl and 2-benzimidazolyl; and (b) a substituted phenyl having the structural formula ##STR4## where R, R' and R" are hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or combinations thereof and the nontoxic pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
16 words
The method of claim 1 wherein R' and R" are halogen radicals and R is hydrogen.
Claim 4
Dependent Claim
21 words
The method of claim 1 wherein R is a hydrogen, R' is a methyl radical and R" is a chloro radical.
Claim 5
Dependent Claim
20 words
The method of claim 1 wherein R is hydrogen, R' is a trihalomethyl radical and R" is a methyl radical.
Claim 6
Dependent Claim
16 words
The method of claim 1 wherein R is hydrogen and R' and R" are methyl radicals.
Claim 7
Dependent Claim
18 words
The method of claim 1 wherein R and R' are chloro radicals and R" is a methyl radical.
Claim 8
Dependent Claim
16 words
The method of claim 1 wherein R and R' are methyl radicals and R" is hydrogen.
Claim 9
Dependent Claim
16 words
The method of claim 1 wherein R and R' are methoxy radicals and R" is hydrogen.
Claim 10
Dependent Claim
25 words
The method of claim 1 wherein the compound is selected from the group consisting of: 2-(2-methylphenylmethoxy)phenol; 2-(3-chlorophenylmethoxy)phenol; 2-(3-trifluoromethylphenylmethoxy)phenol; 2-(4-methoxyphenylmethoxy)phenol; 2-(2,5-dimethylphenylmethoxy)phenol; 2-(2-naphthalenylmethoxy)phenol; 2-(2-pyridylmethoxy)phenol; 2-(2-benzimidazolylmethoxy)phenol; and 2-(2-quinolylmethoxy)phenol.
Claim 11
Dependent Claim
33 words
The method of claim 1 which comprises applying topically to the inflammed area a pharmaceutical composition containing a pharmaceutically acceptable carrier material and from about 0.001 to 5% by weight of the compound.
Claim 12
Dependent Claim
58 words
A pharmaceutical composition for the treatment of inflammation, which composition comprises a pharmaceutically accepted carrier material and from about 0.001% to 5% by weight of a 2-(arylmethoxy)phenol compound selected from the group consisting of: (a) 2-(2-methylphenylmethoxy)phenol; (b) 2-(3-chlorophenylmethoxy)phenol; (c) 2-(3-trifluoromethylphenylmethoxy)phenol; (d) 2-(4-methoxyphenylmethoxy)phenol; (e) 2-(2,5-dimethylphenylmethoxy)phenol; (f) 2-(2-naphthalenylmethoxy)phenol; (g) 2-(2-pyridylmethoxy)phenol; (h) 2-(2-benzimidazolylmethoxy)phenol; and (i) 2-(2-quinolylmethoxy)phenol and their pharmaceutically accepted salts.
Claim 13
Dependent Claim
58 words
A pharmaceutical composition for the treatment of inflammation, which composition comprises a pharmaceutically accepted carrier material and from about 0.001% to 5% by weight of a 2-(arylmethoxy)phenol compound selected from the group consisting of: (a) 2-(2-methylphenylmethoxy)phenol; (b) 2-(3-chlorophenylmethoxy)phenol; (c) 2-(3-trifluoromethylphenylmethoxy)phenol; (d) 2-(4-methoxyphenylmethoxy)phenol; (e) 2-(2,5-dimethylphenylmethoxy)phenol; (f) 2-(2-naphthalenylmethoxy)phenol; (g) 2-(2-pyridylmethoxy)phenol; (h) 2-(2-benzimidazolylmethoxy)phenol; and (i) 2-(2-quinolylmethoxy)phenol and their pharmaceutically accepted salts.
References Cited (Backward Citations)
US1883952A
Cited
US1888827A
Cited
US1933794A
Cited
US3277164A
Cited
US4036844A
Cited
US3968143A
Cited
DE2716125A1
Cited
US4188486A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-01-13 | 1984-07-14 | 1985-01-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-01-13 | 1988-07-14 | 1989-01-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-01-13 | 1992-07-14 | 1993-01-13 | $7700.00 | Window Closed / Lapsed |